The adapted Heart Donor Score

Philipp Angleitner1, Alexandra Kaider2, Jacqueline M. Smits3, Arezu Z. Aliabadi-Zuckermann1, Emilio Osorio-Jaramillo1, Günther Laufer1 & Andreas O. Zuckermann1

1 Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria
2 Center for Medical Statistics, Informatics, and Intelligent Systems (CeMSIIS), Medical University of Vienna, Vienna, Austria
3 Eurotransplant International Foundation, Leiden, The Netherlands

SUMMARY

The Heart Donor Score (HDS) predicts donor organ discard for medical reasons and survival after heart transplantation (HTX) in the Eurotransplant allocation system. Our aim was to adapt the HDS for application in the United Network for Organ Sharing (UNOS) registry. To adjust for differences between the Eurotransplant and UNOS registries, the “adapted HDS” was created (aHDS) by exclusion of the covariates “valve function,” “left-ventricular hypertrophy,” and exclusion of “drug abuse” from the variable “compromised history.” Two datasets were analyzed to evaluate associations of the aHDS with donor organ discard (n = 70,948) and survival (n = 19,279). The aHDS was significantly associated with donor organ discard [odds ratio 2.72, 95% confidence interval (CI) 2.68–2.76, \(P < 0.001\); \(c\)-statistic: 0.937). The score performed comparably in donors <60 and \(\geq 60\) years of age. The aHDS was a significant predictor of survival as evaluated by univariate Cox proportional hazards analysis (hazard ratio 1.04, 95% CI 1.01–1.07, \(P = 0.023\)), although the association lost significance in a multivariable model. The aHDS predicts donor organ discard. Negative effects of most aHDS components on survival are likely eliminated by highly accurate donor selection processes.

Key words
donor, Eurotransplant, heart transplantation, United Network for Organ Sharing

Received: 24 August 2020; Revision requested: 29 September 2020; Accepted: 14 January 2021; Published online: 22 February 2021

Introduction

Adult heart transplantation (HTX) is still limited by scarcity of available donor organs [1–3]. During the last decades, efforts have been made to extend the donor organ pool by increasing acceptance rates of marginal quality donors, characterized by older age, left-ventricular hypertrophy (LVH), or episodes of cardiac arrest, among others [4]. However, a large percentage of marginal quality donor organs is still discarded by heart transplant centers, likely due to concerns about potential penalization of sub-optimal outcomes after HTX [5].

To increase the efficiency of marginal quality donor organ utilization in the Eurotransplant allocation system, the Heart Donor Score (HDS) was developed by Smits et al. [6]. In the original publication, the HDS was demonstrated to be a predictor of donor organ discard for medical reasons and survival after HTX.

Our aim was to create an “adapted HDS” (aHDS) for application in the United Network for Organ Sharing (UNOS) registry. We were interested in the evaluation of donor characteristics that influence the decision processes toward acceptance or discard of donor hearts, the comparison of decision processes between Europe and the United States, and the evaluation of associations between these donor characteristics and survival after HTX.
Patients and methods
The original HDS includes 12 donor characteristics: age, cause of death [cranial trauma, benign brain tumor, malignant brain tumor, circulatory, cerebrovascular accident (CVA), drug overdose, intoxication, carbon monoxide intoxication, meningitis, respiratory, subarachnoid bleeding, sepsis], compromised history (history of drug abuse, malignancy, sepsis, meningitis, positivity for hepatitis B surface antigen, hepatitis B core antibodies, or hepatitis C virus antibodies), hypertension, cardiac arrest, left-ventricular ejection fraction (LVEF), valve function, LVH, coronary angiography, serum sodium, norepinephrine support, and dopamine/dobutamine support [6].

For this analysis, Standard Transplant Analysis and Research files were requested from the UNOS registry. Exemption of full review was granted by the institutional review board of the Medical University of Vienna due to the de-identified nature of the datasets used for statistical analysis. To evaluate the score's performance in the prediction of donor organ discard for medical reasons, we worked with a dataset that included deceased donor organ offers reported to the UNOS registry as of June 8, 2018. To evaluate the score's performance in the prediction of survival after HTX, we analyzed a second dataset that included recipients of primary orthotopic HTX.

Creation of the adapted Heart Donor Score
Exploratory analyses of both UNOS datasets revealed substantial differences in comparison with the Eurotransplant original cohort. First, the HDS components “valve function” and “LVH” are exclusively reported for donors with LVEF <50% in the UNOS registry. As a consequence, both characteristics were missing in >95% of donors [7]. Second, the proportions of donors with a history of drug abuse were substantially higher in the UNOS registry in comparison with the Eurotransplant original cohort, a finding that is in line with recent reports about the “opioid crisis” in the United States [8].

Considering these differences, we created an “adapted HDS” (aHDS) by performing a multivariable logistic regression model based on the UNOS registry data [9,10]. The donor organ discard status (“accepted” versus “discarded for medical reasons”) was defined as the outcome variable, and the original HDS components were included as covariates. The covariates “valve function” and “LVH” were not considered, and the covariate “compromised history” was redefined without “history of drug abuse.” Beta estimates (log odds ratios) of this multivariable regression model were then used as points for calculation of the aHDS: Depending on the donor's individual covariate values the respective beta estimates were summed up to result in the individual aHDS value.

Prediction of donor organ discard for medical reasons
Figure S1 shows the derivation of the study cohort for this analysis. In the UNOS registry, several components of the aHDS were only available between the 1st of July, 2004 and the 28th of February, 2015. Therefore, all donors reported before and after this period were excluded. Moreover, all donors for donation after circulatory death and donors discarded for reasons unrelated to organ quality were excluded. Donors who succumbed to carbon monoxide intoxication were exceedingly rare (n = 3) and therefore excluded as well. Moreover, the aHDS components “cause of death” and “cardiac arrest” were missing for 100 donors and for one donor, respectively. After exclusion of all donors with missing values, the resultant study cohort for this analysis was comprised of 70 948 donors.

Univariate logistic regression analysis was performed to evaluate the aHDS’ association with donor organ discard. Additionally, the previously described multivariable logistic regression model was used to evaluate associations of individual aHDS components with donor organ discard for medical reasons. A receiver operating characteristic curve was generated to visualize the aHDS’ predictive performance. The area under the receiver operating characteristic curve (c-statistic) was calculated to quantify the aHDS’ accuracy in the discrimination between accepted and discarded donor organs.

Additionally, sub-group analyses were conducted to analyze the performance of the aHDS in donors <60 and ≥60 years of age.

Prediction of survival after HTX
Figure S2 shows the derivation of the study cohort for this analysis. Recipients transplanted before the 1st of July, 2004 and after the 28th of February, 2015 were excluded due to the absence of several aHDS components in these periods, as described previously. All recipients under the age of 18 years, recipients of re-transplants, multiorgan transplants, heterotopic transplants, and donation after circulatory death transplants were excluded. A single patient received a heart from a
donor who succumbed due to carbon monoxide intoxication; therefore, this patient was excluded as well. After exclusion of all patients with missing variables, the resultant study cohort for this analysis consisted of 19 279 HTX recipients.

Survival up to 1 year after HTX was defined as the primary outcome variable for this analysis. Death and re-transplantation were considered as equal events. Patients were censored 1 year after HTX or on the 8th of June 2018, respectively. Survival of patients receiving a donor with an aHDS value below the median versus equal to or above the median was visualized using Kaplan–Meier survival curves. The log-rank test was used to compare survival curves of both groups. Univariate and multivariable Cox proportional hazards regression models were created to evaluate associations between the aHDS and survival after HTX. The c-statistic was calculated to quantify the aHDS’ ability to predict survival after HTX. Additionally, a second multivariable Cox proportional hazards regression model including individual aHDS components was generated. Based on clinical experience and published evidence, we determined clinically relevant covariables to be incorporated in both multivariable models, including the components of the Index for Mortality Prediction After Cardiac Transplantation (IMPACT) [11,12]. Proportions of explained variation (PEV) of individual predictors of the second multivariable model were calculated using the method of Schemper and Henderson [13]. The variable “creatinine clearance” was calculated using the Cockcroft–Gault method [14]. Additionally, Kaplan–Meier survival curves out to 10 years after HTX were generated to compare long-term survival rates between recipients of a donor with an aHDS value equal to or above the median versus below the median.

Continuous variables are described by mean values [±standard deviations (SD)]. Variables with skew distributions are depicted by the median (quartiles). Absolute frequencies and percentages are used for the description of categorical variables. All analyses were conducted using SAS software version 9.4 (SAS Institute Inc., 2016. Cary, NC, USA). Two-sided P-values <0.05 were considered statistically significant.

Results

Prediction of donor organ discard for medical reasons

The mean aHDS value was 3.62 (±1.36) for accepted organs and 8.67 (±2.84) for discarded organs, while the median aHDS values amounted to 3.59 (2.97–4.06) and 8.59 (6.76–11.11), respectively (Table 1, Fig. 1). Donors with an aHDS values ≥5 were more frequently discarded than accepted (Fig. 1).

The majority of accepted donors was younger than 45 years of age (84.5%; Table 1). Cranial trauma was the most common cause of death for accepted donors (58.1%), while discarded donors most commonly succumbed to CVA (51.4%). Notably, the proportions of donors with compromised history were substantially higher in the UNOS registry when compared with the Eurotransplant cohort as described in the original publication (accepted donors: 9.8% vs. 2.1%) [6]. Normal coronary angiography results were more common for accepted donors when compared with discarded donors (20.5% vs. 2.2%). High dosages of norepinephrine and dopamine/dobutamine support were rare for both accepted and discarded donors.

Univariate logistic regression analysis demonstrated that the aHDS was significantly associated with donor organ discard for medical reasons [odds ratio (OR; per increase of one point) 2.72, 95% confidence interval (CI) 2.68–2.76; OR (per increase of one SD) 30.6, 95% CI 29.0–32.2; P < 0.001]. A multivariable logistic regression model showed that all individual components of the aHDS with the exception of “cardiac arrest” (P = 0.630) were independently associated with donor organ discard for medical reasons (Table 2). Figure 2 visualizes the receiver operating characteristic curve of the aHDS with a c-statistic of 0.937.

Donors <60 years and ≥60 years of age

Table 3 shows baseline characteristics of donors <60 and ≥60 years of age. In donors <60 years of age, the mean aHDS value was 3.61 (±1.35) for accepted organs and 7.72 (±2.50) for discarded organs, while the median aHDS values amounted to 3.58 (2.97–4.05) and 7.71 (5.88–9.83), respectively (Table 3, Fig. 3). Donors ≥60 years of age presented with substantially higher aHDS values for both accepted organs (mean: 5.91 ± 1.72; median 5.58, 4.60–6.85) and discarded organs (mean: 11.63 ± 1.46; median: 12.09, 11.13–12.35; Fig. 4). Figure 4 clearly shows that the vast majority of donors ≥60 years of age was discarded. Accepted donors ≥60 years of age most commonly succumbed to CVA (65.6%) and rarely had a history of cardiac arrest (0.8%). Donors ≥60 years of age who presented with an LVEF <45% or with an unreported LVEF were uniformly discarded. The vast majority of older donors that were accepted had normal coronary
Angiography results (75.4%). All donors ≥60 years of age with norepinephrine support >0.4 µg/kg/min or dopamine/dobutamine support >7.5 µg/kg/min were discarded (Table 3).

Analyzing only donors <60 years of age, the aHDS was significantly associated with donor organ discard for medical reasons (OR 2.71, 95% CI 2.66–2.75; P < 0.001). The c-statistic in this group amounted to 0.919. In donors ≥60 years of age, the aHDS was similarly associated with donor organ discard (OR 3.26, 95% CI 2.89–3.67; P < 0.001) with a c-statistic of 0.983.

Prediction of survival after HTX

Table 4 shows baseline characteristics of the study cohort for the survival analysis. The mean aHDS value of HTX recipients was 3.48 (±1.34), while the median aHDS value amounted to 3.53 (2.92–4.00). Most recipients received donors younger than 45 years of age (81.6%) with cranial trauma being the most common cause of death (58.7%). Most transplanted patients received a donor without compromised history (89.8%). Coronary angiography results were not available for the majority of transplanted donor hearts (73.4%). The median IMPACT Score of all recipients was 5.0 (3.0–7.0). The mean recipient age was 52.7 (±12.6) years and the mean ischemic time amounted to 3.24 (±1.05) hours.

| Variables | N = 70 948 (100%) |
|-----------|-------------------|
|          | Accepted organs | Discarded organs |
|          | N = 25 049 (35.3%) | N = 45 899 (64.7%) |
| aHDS (mean) | 3.62 ± 1.36 | 8.67 ± 2.84 |
| aHDS (median) | 3.59 | 8.59 (6.76–11.11) |
| Age (year) |          |          |
| <45      | 21 165 (84.5%) | 16 859 (36.7%) |
| 45–54    | 3203 (12.8%) | 11 867 (25.9%) |
| 55–59    | 559 (2.2%) | 6022 (13.1%) |
| ≥60      | 122 (0.5%) | 11 151 (24.3%) |
| Cause of death |          |          |
| Cranial trauma | 14 542 (58.1%) | 11 277 (24.6%) |
| Benign BT | 121 (0.5%) | 110 (0.2%) |
| Malignant BT | 78 (0.3%) | 110 (0.2%) |
| Circulatory | 1518 (6.1%) | 5914 (12.9%) |
| CVA     | 5053 (20.2%) | 23 569 (51.4%) |
| Drug overdose | 1287 (5.1%) | 1899 (4.1%) |
| Intoxication | 12 (0.1%) | 12 (0.0%) |
| Meningitis | 94 (0.4%) | 155 (0.3%) |
| Respiratory | 2277 (9.1%) | 2677 (5.8%) |
| SAB     | 25 (0.1%) | 11 151 (24.3%) |
| Sepsis | 42 (0.2%) | 75 (0.2%) |
| Donor history |          |          |
| Uncompromised | 22 590 (90.2%) | 35 053 (76.4%) |
| Compromised | 2459 (9.8%) | 10 846 (23.6%) |
| Hypertension |          |          |
| No      | 21 924 (87.5%) | 23 952 (52.2%) |
| Yes    | 3011 (12.0%) | 21 593 (47.0%) |
| Not available | 114 (0.5%) | 354 (0.8%) |
| Cardiac arrest |          |          |
| No      | 23 367 (93.3%) | 42 456 (92.5%) |
| Yes    | 1682 (6.7%) | 3443 (7.5%) |
| LVEF (%) |          |          |
| >55     | 18 383 (73.4%) | 10 932 (23.8%) |
| 45–55   | 5992 (23.9%) | 6408 (14.0%) |
| <45    | 263 (1.1%) | 6752 (14.7%) |
| Not available | 411 (1.6%) | 21 807 (47.5%) |
| Coronary angiography |          |          |
| Normal | 5132 (20.5%) | 1018 (2.2%) |
| Irregularities | 471 (1.9%) | 2051 (4.5%) |
| 1-vessel stenosis | 32 (0.1%) | 630 (1.4%) |
| >1-vessel stenosis | 10 (0.0%) | 616 (1.3%) |
| Not available | 19 404 (77.5%) | 41 584 (90.6%) |
| Serum sodium (mmol/l) |          |          |
| <130    | 641 (2.6%) | 965 (2.1%) |
| 130–139 | 4201 (16.8%) | 7648 (16.7%) |
| 140–149 | 10 096 (40.3%) | 19 855 (43.3%) |
| 150–159 | 8072 (32.2%) | 14 140 (30.8%) |
| 160–164 | 1292 (5.2%) | 2093 (4.6%) |
| 165–169 | 501 (2.0%) | 782 (1.7%) |
| ≥170   | 208 (0.8%) | 351 (0.8%) |
| Not available | 38 (0.2%) | 65 (0.1%) |

Table 1. Continued.

| Variables | N = 70 948 (100%) |
|-----------|-------------------|
|          | Accepted organs | Discarded organs |
|          | n = 25 049 (35.3%) | N = 45 899 (64.7%) |
| Norepinephrine (µg/kg/min) |          |          |
| <0.1      | 19 008 (75.9%) | 31 776 (69.2%) |
| 0.1–0.4   | 803 (3.2%) | 4032 (8.8%) |
| 0.41–0.8  | 115 (0.5%) | 744 (1.6%) |
| >0.8      | 19 (0.1%) | 82 (0.2%) |
| Not available | 5104 (20.4%) | 9265 (20.2%) |
| Dopamine/dobutamine (µg/kg/min) |          |          |
| <5        | 17 527 (70.0%) | 29 444 (64.1%) |
| 5–7.5     | 1993 (8.0%) | 3945 (8.6%) |
| 7.51–10   | 846 (3.4%) | 2546 (5.6%) |
| >10       | 258 (1.0%) | 1226 (2.7%) |
| Not available | 4425 (17.7%) | 8738 (19.0%) |

aHDS, adapted Heart Donor Score; BT, brain tumor; CVA, cerebrovascular accident; LVEF, left-ventricular ejection fraction; SAB, subarachnoid bleeding.
Univariate Cox proportional hazards regression analysis showed a significant association of the aHDS with survival up to 1 year after HTX [hazard ratio (HR; per increase of one point) 1.04, 95% CI 1.01–1.07; HR (per increase of one SD) 1.05, 95% CI 1.01–1.10; \( P = 0.023 \)] (Table 5). The \( c \)-statistic of this model amounted to 0.514. Figure 5 visualizes Kaplan–Meier survival curves of HTX recipients stratified along the median aHDS value of 3.53. Survival rates at 1 year after HTX amounted to 88.9% (95% CI, 88.2–89.5%) for patients receiving a donor with an aHDS value \( \geq 3.53 \) and 89.9% (95% CI, 89.3–90.5%) for patients receiving a donor with an aHDS value <3.53 (log-rank test, \( P = 0.021 \)). Figure S3 shows Kaplan–Meier survival curves out to 10 years after HTX. Survival rates at 3 years amounted to 82.4% (95% CI, 81.6–83.2%) for recipients of a donor with an aHDS value \( \geq 3.53 \) and 83.3% (95% CI, 82.6–84.1%) for those with an aHDS value <3.53 (5 years: aHDS \( \geq 3.53 \): 76.0%, 95% CI 75.1–76.9%; aHDS <3.53: 77.1%, 95% CI 76.2–78.0%).

Additionally, a multivariable Cox proportional hazards regression model including clinically relevant covariables was created: IMPACT Score, male donor sex, recipient body mass index, recipient diabetes, transplant year, transplant urgency, and ischemic time. Before statistical analysis, patients with missing variables were excluded (IMPACT Score: \( n = 1080 \); bilirubin: \( n = 330 \); creatinine clearance: \( n = 73 \); dialysis between listing and HTX: \( n = 160 \); infection: \( n = 544 \); ventricular assist device: \( n = 205 \); recipient body mass index: \( n = 3 \); recipient diabetes: \( n = 74 \); ischemic time: \( n = 338 \)). Consequently, the model was calculated with 17,868 patients.

In the multivariable Cox proportional hazards regression model, the aHDS was not significantly associated with survival up to 1 year after HTX [HR (per increase of one point) 1.01, 95% CI 0.98–1.05; HR (per increase of one SD) 1.02, 95% CI 0.97–1.07; \( P = 0.425 \)] (Table 5). A second multivariable Cox proportional hazards regression model that included all individual aHDS components showed that only donor age was independently and significantly associated with survival after HTX (\( P < 0.001 \)) (Table 6). In this model, PEV values were highest for the variables “IMPACT Score” (1.20%) and “ischemic time” (0.22%).

Discussion

The present study provides several insights. First, our analysis shows that the aHDS accurately predicts donor organ discard for medical reasons in the UNOS registry, with a \( c \)-statistic of 0.937 (Fig. 2). Donors with an aHDS value \( \geq 5 \) are more frequently discarded than accepted (Fig. 1). These findings are in line with a
| Variable               | Beta-estimate | Odds ratio | 95% CI of odds ratio | P-value |
|------------------------|---------------|------------|----------------------|---------|
| **Age (year)**         |               |            |                      |         |
| <45                    | 0             | 1.00       | –                    | <0.001  |
| 45–54                  | 1.85          | 6.34       | 5.87–6.84            |         |
| 55–59                  | 2.61          | 13.62      | 11.91–15.56          |         |
| ≥60                    | 3.67          | 39.29      | 31.45–49.09          |         |
| **Cause of death**     |               |            |                      |         |
| Cranial trauma         | 0             | 1.00       | –                    | <0.001  |
| Benign BT              | 0.13          | 1.14       | 0.80–1.63            |         |
| Malignant BT           | –0.01         | 0.99       | 0.66–1.49            |         |
| Circulatory            | 1.09          | 2.98       | 2.72–3.26            |         |
| CVA                    | 0.93          | 2.53       | 2.38–2.70            |         |
| Drug overdose          | 0.88          | 2.40       | 2.17–2.66            |         |
| Intoxication           | 0.96          | 2.60       | 0.90–7.51            |         |
| Meningitis             | 0.32          | 1.38       | 0.99–1.92            |         |
| Respiratory            | 0.50          | 1.65       | 1.51–1.80            |         |
| SAB                    | 0.59          | 1.81       | 0.90–3.67            |         |
| Sepsis                 | 0.40          | 1.49       | 0.90–2.48            |         |
| **Donor history**      |               |            |                      |         |
| Uncompromised          | 0             | 1.00       | –                    | <0.001  |
| Compromised            | 0.81          | 2.24       | 2.09–2.41            |         |
| **Hypertension**       |               |            |                      |         |
| No                     | 0             | 1.00       | –                    | <0.001  |
| Yes                    | 1.06          | 2.90       | 2.71–3.10            |         |
| Not available           | 0.79          | 2.20       | 1.60–3.01            |         |
| **Cardiac arrest**     |               |            |                      |         |
| No                     | 0             | 1.00       | –                    | 0.630   |
| Yes                    | 0.02          | 1.02       | 0.93–1.12            |         |
| **LVEF (%)**           |               |            |                      | <0.001  |
| >55                    | 0             | 1.00       | –                    |         |
| 45–55                  | 0.76          | 2.14       | 2.03–2.26            |         |
| <45                    | 4.25          | 69.79      | 61.13–79.68          |         |
| Not available           | 3.50          | 33.24      | 29.84–37.03          |         |
| **Coronary angiography** |             |            |                      | <0.001  |
| Normal                 | 0             | 1.00       | –                    |         |
| Irregularities         | 3.73          | 41.76      | 36.15–48.25          |         |
| 1-vessel stenosis      | 4.97          | 143.52     | 97.37–211.55         |         |
| >1-vessel stenosis     | 5.95          | 384.82     | 200.75–737.68        |         |
| Not available           | 2.98          | 19.65      | 17.81–21.68          |         |
| **Serum sodium (mmol/l)** |           |            |                      | 0.038   |
| <130                   | –0.19         | 0.83       | 0.70–0.97            |         |
| 130–139                | –0.07         | 0.93       | 0.87–1.00            |         |
| 140–149                | 0             | 1.00       | –                    |         |
| 150–159                | –0.05         | 0.95       | 0.90–1.00            |         |
| 160–164                | –0.03         | 0.97       | 0.87–1.09            |         |
| 165–169                | 0.06          | 1.06       | 0.89–1.26            |         |
| ≥170                   | 0.22          | 1.25       | 0.97–1.60            |         |
| Not available           | –0.18         | 0.83       | 0.45–1.53            |         |
| **Norepinephrine (µg/kg/min)** |       |            |                      | <0.001  |
| <0.1                   | 0             | 1.00       | –                    |         |
| 0.1–0.4                | 0.79          | 2.21       | 1.97–2.48            |         |
| 0.41–0.8               | 0.82          | 2.28       | 1.73–3.01            |         |
| >0.8                   | 0.60          | 1.83       | 0.90–3.69            |         |
| Not available           | 0.05          | 1.05       | 0.98–1.12            |         |
report from the 2015 American Society of Transplantation Conference on Donor Heart Selection, showing that experts in the transplant community rank the variables “donor age,” “LVEF,” “LVH,” “ischemic time,” and “high inotrope use” among the most important risk factors during the donor selection process [5]. Additionally, “donor-recipient sex mismatch,” “coronary artery disease,” and “malignancy” are considered important risk factors. Most of these variables are components of the aHDS, and our results confirm that they are significantly associated with donor organ discard in this real-world registry (Table 2). A previously published analysis of the UNOS registry reported comparable results. In this study, “older age,” “lower LVEF,” “tumor as a cause of death,” and “presence of inotrope support” were significantly associated with donor organ discard [15]. Similarly, a study utilizing the California Transplant Donor Network database showed that “age over 50 years,” “CVA as a cause of death,” “hypertension,” “reduced LVEF,” and other variables were predictive of donor organ discard [16].

Second, our analysis suggests that similar donor characteristics are considered by transplant physicians in Europe and the United States during the decision processes toward acceptance or discard of specific donor hearts. However, the past 3 decades have seen a trend toward substantially increasing median donor age in Europe (31–45 years), but not in North America (28–31 years) [17]. Indeed, Table 2 demonstrates that “age ≥60 years” has an OR of 39.29 for donor organ discard in the UNOS registry, and Table 3 shows that only 1.1% of donors ≥60 years are accepted for HTX. Future studies are required to analyze how these changing acceptance practices regarding “donor age” in Europe will translate into outcomes after HTX.

Third, our analyses show that the aHDS is similarly predictive of donor organ discard in donors <60 and ≥60 years of age. Importantly, Table 3 suggests that only highly selected donors ≥60 years of age were accepted for HTX, given that only 0.8% of them presented with a history of cardiac arrest, none of them presented with an LVEF <45% or an unreported LVEF, and none of them required higher dose norepinephrine or dopamine/dobutamine support (Table 3). In the literature, interactions between donor age and other donor variables have been reported. For example, prolonged ischemic time in combination with a donor heart of advanced age is associated with significantly inferior survival in comparison with the same ischemic time in a younger donor heart [17]. Therefore, transplant physicians most likely accepted donors ≥60 years of age only if their risk profile was otherwise low in order to avoid excessive accumulation of donor risk.

### Table 2. Continued.

| Variable | Beta-estimate | Odds ratio | 95% CI of odds ratio | P-value |
|----------|--------------|------------|----------------------|---------|
| Dopamine/dobutamine (µg/kg/min) | | | | <0.001 |
| <5 | 0 | 1.00 | – | |
| 5–7.5 | 0.16 | 1.18 | 1.08–1.29 | |
| 7.51–10 | 0.58 | 1.79 | 1.59–2.01 | |
| >10 | 0.89 | 2.44 | 2.02–2.96 | |
| Not available | 0.15 | 1.16 | 1.08–1.24 | |

BT, brain tumor; CVA, cerebrovascular accident; LVEF, left-ventricular ejection fraction; SAB, subarachnoid bleeding. Bold indicates statistical significance (P < 0.05).
| Variables | Age < 60 years | | | Age ≥ 60 years | | |
|-----------|----------------|----------------|----------------|----------------|----------------|
| | Accepted organs | Discarded organs | Accepted organs | Discarded organs |
| | n = 24 927 (41.8%) | N = 34 748 (58.2%) | n = 122 (1.1%) | N = 11 151 (98.9%) |
| aHDS (mean) | 3.61 ± 1.35 | 7.72 ± 2.50 | 5.91 ± 1.72 | 11.63 ± 1.46 |
| aHDS (median) | 3.58 (2.97–4.05) | 7.71 (5.88–8.83) | 5.58 (4.60–6.85) | 12.09 (11.13–12.35) |
| Age (year) |  |  |  |  |
| <45 | 21 165 (84.9%) | 16 859 (48.5%) | 0 (0%) | 0 (0%) |
| 45–54 | 3203 (12.9%) | 11 867 (34.2%) | 0 (0%) | 0 (0%) |
| 55–59 | 559 (2.2%) | 6022 (17.3%) | 0 (0%) | 0 (0%) |
| ≥60 | 0 (0%) | 122 (100%) | 11 151 (100%) |  |
| Cause of death |  |  |  |  |
| Cranial trauma | 14 510 (58.2%) | 9697 (27.9%) | 32 (26.2%) | 1580 (14.2%) |
| Benign BT | 121 (0.5%) | 117 (0.3%) | 0 (0.0%) | 13 (0.1%) |
| Malignant BT | 77 (0.3%) | 97 (0.3%) | 1 (0.8%) | 13 (0.1%) |
| Circulatory | 1511 (6.1%) | 4722 (13.6%) | 7 (5.7%) | 1192 (10.7%) |
| CVA | 4973 (20.0%) | 15 552 (44.8%) | 80 (65.6%) | 8017 (71.9%) |
| Drug overdose | 1287 (5.2%) | 1867 (5.4%) | 0 (0.0%) | 32 (0.3%) |
| Intoxication | 12 (0.1%) | 12 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Meningitis | 93 (0.4%) | 150 (0.4%) | 1 (0.8%) | 5 (0.0%) |
| Respiratory | 2277 (9.1%) | 2420 (7.0%) | 0 (0.0%) | 257 (2.3%) |
| SAB | 24 (0.1%) | 50 (0.1%) | 1 (0.8%) | 31 (0.3%) |
| Seppis | 42 (0.2%) | 64 (0.2%) | 0 (0.0%) | 11 (0.1%) |
| Donor history |  |  |  |  |
| Uncompromised | 22 494 (90.2%) | 26 614 (76.6%) | 96 (78.7%) | 8439 (75.7%) |
| Compromised | 2433 (9.8%) | 8134 (23.4%) | 26 (21.3%) | 2712 (24.3%) |
| Hypertension |  |  |  |  |
| No | 21 849 (87.7%) | 20 615 (59.3%) | 75 (61.5%) | 3337 (29.9%) |
| Yes | 2964 (11.9%) | 13 862 (39.9%) | 47 (38.5%) | 7731 (69.3%) |
| Not available | 114 (0.5%) | 271 (0.8%) | 0 (0.0%) | 83 (0.7%) |
| Cardiac arrest |  |  |  |  |
| No | 23 246 (93.3%) | 31 917 (91.9%) | 121 (99.2%) | 10 539 (94.5%) |
| Yes | 1681 (6.7%) | 2831 (8.2%) | 1 (0.8%) | 612 (5.5%) |
| LVEF (%) |  |  |  |  |
| >55 | 18 279 (73.3%) | 9869 (28.4%) | 104 (85.3%) | 1063 (9.5%) |
| 45–55 | 5974 (24.0%) | 5875 (16.9%) | 18 (14.8%) | 533 (4.8%) |
| <45 | 263 (1.1%) | 6448 (18.6%) | 0 (0.0%) | 304 (2.7%) |
| Not available | 411 (1.7%) | 12 556 (36.1%) | 0 (0.0%) | 9251 (83.0%) |
| Coronary angiography |  |  |  |  |
| Normal | 5040 (20.2%) | 938 (2.7%) | 92 (75.4%) | 80 (0.7%) |
| Irregularities | 465 (1.9%) | 1907 (5.5%) | 6 (4.9%) | 144 (1.3%) |
| 1-vessel stenosis | 31 (0.1%) | 566 (1.6%) | 1 (0.8%) | 64 (0.6%) |
| >1-vessel stenosis | 8 (0.0%) | 547 (1.6%) | 2 (1.6%) | 69 (0.6%) |
| Not available | 19 383 (77.8%) | 30 790 (88.6%) | 21 (17.2%) | 10 794 (96.8%) |
| Serum sodium (mmol/l) |  |  |  |  |
| <130 | 637 (2.6%) | 818 (2.4%) | 4 (3.3%) | 147 (1.3%) |
| 130–139 | 4185 (16.8%) | 5913 (17.0%) | 16 (13.1%) | 1735 (15.6%) |
| 140–149 | 10 043 (40.3%) | 14 570 (41.9%) | 53 (43.4%) | 5285 (47.4%) |
| 150–159 | 8031 (32.2%) | 10 751 (30.9%) | 41 (33.6%) | 3389 (30.4%) |
| 160–164 | 1288 (5.2%) | 1680 (4.8%) | 4 (3.3%) | 413 (3.7%) |
| 165–169 | 498 (2.0%) | 651 (1.9%) | 3 (2.5%) | 131 (1.2%) |
| ≥170 | 208 (0.8%) | 310 (0.9%) | 0 (0.0%) | 41 (0.4%) |
| Not available | 37 (0.2%) | 55 (0.2%) | 1 (0.8%) | 10 (0.1%) |
| Norepinephrine (µg/kg/min) |  |  |  |  |
| <0.1 | 18 914 (75.9%) | 24 091 (69.3%) | 94 (77.1%) | 7685 (68.9%) |
Fourth, survival analyses show that the aHDS individually predicts survival after HTX, although the effect becomes nonsignificant after adjustment for the IMPACT Score and other recipient and procedural variables (Table 5). Detailed analysis of individual aHDS components demonstrates that donor age is significantly and independently associated with 1-year survival after HTX (Table 6). This finding is in line with a multitude of published analyses, including the widely recognized “donor risk score” by Weiss et al. [18] Fig. 5 illustrates that the 1-year survival rates of recipients stratified along the median aHDS are significantly different, although this difference likely is of minimal clinical relevance (88.9% vs. 89.9%). Moreover, PEV values in Table 6 are comparably small for most aHDS components.

We believe that two hypotheses are feasible to explain the absence of an independent association of the aHDS

| Table 3. Continued. |
|----------------------|
| Variables | Age < 60 years N = 59 675 (100%) | | Age ≥ 60 years N = 11 273 (100%) |
| | Accepted organs n = 24 927 (41.8%) | Discarded organs N = 34 748 (58.2%) | Accepted organs n = 122 (1.1%) | Discarded organs N = 11 151 (98.9%) |
| 0.1–0.4 | 800 (3.2%) | 2985 (8.6%) | 3 (2.5%) | 1047 (9.4%) |
| 0.41–0.8 | 115 (0.5%) | 567 (1.6%) | 0 (0.0%) | 177 (1.6%) |
| >0.8 | 19 (0.1%) | 65 (0.2%) | 0 (0.0%) | 17 (0.2%) |
| Not available | 5079 (20.4%) | 7040 (20.3%) | 25 (20.5%) | 2225 (20.0%) |
| Dopamine/dobutamine (µg/kg/min) | | | | |
| <5 | 17 432 (69.9%) | 22 049 (63.5%) | 95 (77.9%) | 7395 (66.3%) |
| 5–7.5 | 1985 (8.0%) | 3034 (8.7%) | 8 (6.6%) | 911 (8.2%) |
| 7.51–10 | 846 (3.4%) | 1951 (5.6%) | 0 (0.0%) | 595 (5.3%) |
| >10 | 258 (1.0%) | 949 (2.7%) | 0 (0.0%) | 277 (2.5%) |
| Not available | 4406 (17.7%) | 6765 (19.5%) | 19 (15.6%) | 1973 (17.7%) |

*aHDS, adapted Heart Donor Score; BT, brain tumor; CVA, cerebrovascular accident; LVEF, left-ventricular ejection fraction; SAB, subarachnoid bleeding.*

**Figure 3** Donors <60 years of age. In donors <60 years of age, the mean aHDS value was 3.61 (±1.35) for accepted organs and 7.72 (±2.50) for discarded organs, while the median aHDS values amounted to 3.58 (2.97–4.05) and 7.71 (5.88–9.83), respectively.
with survival. Primarily, our notion is that donor selection processes and decision making of transplant physicians in the United States are highly accurate, thereby eliminating the potentially negative effects of most aHDS components and leaving only donor age with a significant and independent influence on 1-year survival after HTX (Table 6).

Alternatively, the components of the aHDS with the exception of “donor age” might be of inferior importance for survival after HTX. This explanation would be in line with a recently growing body of literature, showing that marginal quality donor hearts might be safely accepted without compromising outcomes after HTX. Specifically, our group has shown that higher dose norepinephrine donor support is not associated with impaired survival or higher rates of primary graft dysfunction, prolonged ventilation, or renal replacement therapy after HTX [19]. Moreover, studies have shown that recipients of donors with even markedly reduced LVEF are not at risk of impaired long-term survival, dopamine donor support is actually associated with superior survival after HTX, and recipients of donor hearts with documented single-vessel disease have similar survival when compared with recipients of donor hearts without coronary atherosclerosis [20–23].

We believe that the aHDS might be used clinically to standardize donor acceptance criteria and define “high-risk donors,” thereby potentially reducing variability in acceptance practices between transplant centers [24]. As suggested by Smith et al., standardization of the donor selection process might enable transplant centers to increase the utilization rates of marginal quality donor organs without compromising survival rates after HTX [25]. Moreover, the aHDS might be implemented to raise efficiency of the allocation process. Chances of acceptance or discard might be estimated for specific donor hearts early on in the allocation process, thereby offering a possibility to efficiently guide resource allocation, including transport for organ procurement or operative suite utilization.

Limitations

Several limitations need to be considered when interpreting the presented results. First, retrospective registry analyses are subject to selection bias. Most donors presenting with characteristics at the extremes of the range (e.g., age >80 years, LVEF <10%) have likely not been reported to the UNOS registry from the outset. Therefore, the true influence of extreme donor characteristics and consequently aHDS values on outcomes after HTX is inherently in-examinable. Second, the recent changes in the United States heart allocation system could not be considered in this analysis of the period 2004–2015. Third, the recently increasing utilization of hepatitis C positive donors and donation after circulatory death

Figure 4 Donors ≥60 years of age. Donors ≥60 years of age presented with substantially higher aHDS values for both accepted organs (mean: 5.91 ± 1.72; median 5.58, 4.60–6.85) and discarded organs (mean: 11.63 ± 1.46; median: 12.09, 11.13–12.35).
Table 4. Prediction of survival after HTX (baseline characteristics).

| Variables                        | HTX recipients | N = 19 279 (100%) |
|----------------------------------|----------------|-------------------|
| aHDS (mean ± SD)                 | 3.48 ± 1.34    |                   |
| aHDS (median [quartiles])        | 3.53 (2.92–4.00) |               |
| aHDS components                  |                |                   |
| Donor age (year)                 |                |                   |
| <45                              | 15 739 (81.6%) |                   |
| 45–54                            | 2924 (15.2%)   |                   |
| 55–59                            | 502 (2.6%)     |                   |
| ≥60                              | 114 (0.6%)     |                   |
| Cause of death                   |                |                   |
| Cranial trauma                   | 11 312 (58.7%) |                   |
| Benign BT                        | 93 (0.5%)      |                   |
| Malignant BT                     | 62 (0.3%)      |                   |
| Circulatory                      | 1027 (5.3%)    |                   |
| CVA                              | 4312 (22.4%)   |                   |
| Drug overdose                     | 1106 (5.7%)    |                   |
| Intoxication                     | 11 (0.1%)      |                   |
| Meningitis                       | 67 (0.4%)      |                   |
| Respiratory                      | 1243 (6.5%)    |                   |
| SAB                              | 21 (0.1%)      |                   |
| Sepsis                           | 25 (0.1%)      |                   |
| Donor history                    |                |                   |
| Uncompromised                    | 17 315 (89.8%) |                   |
| Compromised                      | 1964 (10.2%)   |                   |
| Hypertension                     |                |                   |
| No                               | 16 448 (85.3%) |                   |
| Yes                              | 2728 (14.2%)   |                   |
| Not available                     | 103 (0.5%)     |                   |
| Cardiac arrest                   |                |                   |
| No                               | 18 074 (93.8%) |                   |
| Yes                              | 1205 (6.2%)    |                   |
| LVEF (%)                         |                |                   |
| >55                              | 13 988 (72.6%) |                   |
| 45–55                            | 4991 (25.9%)   |                   |
| <45                              | 144 (0.8%)     |                   |
| Not available                     | 156 (0.8%)     |                   |
| Coronary angiography             |                |                   |
| Normal                           | 4780 (24.8%)   |                   |
| Irregularities                   | 320 (1.7%)     |                   |
| 1-vessel stenosis                | 28 (0.2%)      |                   |
| >1-vessel stenosis               | 8 (0.0%)       |                   |
| Not available                     | 14 143 (73.4%) |                   |
| Serum sodium (mmol/l)            |                |                   |
| <130                             | 335 (1.7%)     |                   |
| 130–139                          | 3015 (15.6%)   |                   |
| 140–149                          | 7851 (40.7%)   |                   |
| 150–159                          | 6490 (33.7%)   |                   |
| 160–164                          | 1008 (5.2%)    |                   |
| 165–169                          | 390 (2.0%)     |                   |
| ≥170                             | 165 (0.9%)     |                   |
| Not available                     | 25 (0.1%)      |                   |

Table 4. Continued.

| Variables                                      | HTX recipients | N = 19 279 (100%) |
|------------------------------------------------|----------------|-------------------|
| Norepinephrine (µg/kg/min)                     |                |                   |
| <0.1                                           | 14 299 (74.2%) |                   |
| 0.1–0.4                                        | 614 (3.2%)     |                   |
| 0.41–0.8                                       | 83 (0.4%)      |                   |
| >0.8                                           | 14 (0.1%)      |                   |
| Not available                                  | 4269 (22.1%)   |                   |
| Dopamine/dobutamine (µg/kg/min)                |                |                   |
| <5                                              | 13 785 (71.5%) |                   |
| 5–7.5                                          | 1449 (7.5%)    |                   |
| 7.51–10                                        | 555 (2.9%)     |                   |
| >10                                            | 159 (0.8%)     |                   |
| Not available                                  | 3331 (17.3%)   |                   |
| IMPACT score (1080 missing)                    | 5.0 (3.0–7.0)  |                   |
| IMPACT score components                        |                |                   |
| Recipient age (year)                           |                |                   |
| No                                             | 18 741 (98.0%) |                   |
| Yes                                            | 378 (2.0%)     |                   |
| Female sex                                     | 4790 (24.8%)   |                   |
| Diagnosis                                       |                |                   |
| Dilatative cardiomyopathy                      | 9108 (47.3%)   |                   |
| Ischemic cardiomyopathy                        | 7931 (41.1%)   |                   |
| Congenital heart disease                       | 583 (3.0%)     |                   |
| Other                                           | 1657 (8.6%)    |                   |
| Infection (544 missing)                        |                |                   |
| No                                             | 16 695 (89.1%) |                   |
| Yes                                            | 2040 (10.9%)   |                   |
| Intra-aortic balloon pump                      |                |                   |
| No                                             | 18 263 (94.7%) |                   |
| Yes                                            | 1016 (5.3%)    |                   |
| Mechanical ventilation                         |                |                   |
| No                                             | 18 917 (98.1%) |                   |
| Yes                                            | 362 (1.9%)     |                   |
| Ethnicity                                       |                |                   |
| Caucasian                                       | 13 304 (69.0%) |                   |
| African American                                | 3718 (19.3%)   |                   |
| Hispanic                                        | 1471 (7.6%)    |                   |
| Other                                           | 786 (4.1%)     |                   |
| Temporary circulatory support                   |                |                   |
| No                                             | 18 934 (98.2%) |                   |
| Yes                                            | 345 (1.8%)     |                   |
| Ventricular assist device (205 missing)        |                |                   |
| No ventricular assist device                    | 12 610 (66.1%) |                   |
| Old generation pulsatile                       | 1510 (7.9%)    |                   |
| New generation continuous                       | 257 (1.4%)     |                   |
| Abbott HeartMate II® or HeartWare® HVAD®       | 4697 (24.6%)   |                   |
| Other variables                                 |                |                   |
| Donor male sex                                  | 13 828 (71.7%) |                   |
aHDS, adapted Heart Donor Score; BT, brain tumor; CVA, cerebrovascular accident; HTX, heart transplantation; IMPACT, Index for Mortality Prediction after Cardiac Transplantation; LVEF, left-ventricular ejection fraction; SAB, subarachnoid bleeding.

Fourth, the anonymized nature of the datasets underlying this retrospective registry analysis limited the possibilities to perform structured audits for data entry errors.

**Table 5.** Prediction of survival after HTX (univariate and multivariable cox proportional hazards regression analyses).

| Variable                      | Hazard ratio | 95% Confidence interval | P-value |
|-------------------------------|--------------|--------------------------|---------|
| Univariate analysis           |              |                          |         |
| aHDS                          |              |                          |         |
| Per increase of one point     | 1.04         | 1.01–1.07                | 0.023   |
| Per increase of one SD        | 1.05         | 1.01–1.10                |         |
| Multivariable model           |              |                          |         |
| aHDS                          |              |                          |         |
| Per increase of one point     | 1.01         | 0.98–1.05                |         |
| Per increase of one SD        | 1.02         | 0.97–1.07                |         |
| IMPACT score (log2-transformed) | 1.47      | 1.40–1.54                | <0.001  |
| Male donor sex                | 0.91         | 0.82–1.01                | 0.065   |
| Recipient body mass Index (kg/m²) | 1.02     | 1.01–1.03                | <0.001  |
| Recipient diabetes            | 1.03         | 0.93–1.14                | 0.622   |
| Transplant year               | 0.98         | 0.96–0.99                | 0.003   |
| Transplant urgency            |              |                          |         |
| Status 1A                     | 0.94         | 0.81–1.10                | 0.294   |
| Status 1B                     | 0.89         | 0.76–1.04                |         |
| Status 2                      | 1.00         | –                        |         |
| Ischemic time (h)             | 1.15         | 1.10–1.20                | <0.001  |

aHDS, adapted Heart Donor Score; IMPACT, Index for Mortality Prediction after Cardiac Transplantation; SD, standard deviation. Bold indicates statistical significance (P < 0.05).
Table 6. Prediction of survival after HTX (multivariable cox proportional hazards regression analysis of aHDS components).

| Variable                     | Hazard ratio | 95% Confidence interval | P-value | Proportion of explained variation (%) |
|------------------------------|--------------|--------------------------|---------|---------------------------------------|
| Age (year)                   |              |                          |         |                                       |
| <45                          | 1.00         | –                        | <0.001  | 0.09                                  |
| 45–54                        | 1.31         | 1.13–1.52                |         |                                       |
| 55–59                        | 1.47         | 1.13–1.90                |         |                                       |
| ≥60                          | 1.27         | 0.75–2.14                |         |                                       |
| Cause of death               |              |                          |         |                                       |
| Cranial trauma               | 1.00         | –                        | 0.060   | 0.09                                  |
| Benign BT                    | 1.49         | 0.86–2.59                |         |                                       |
| Malignant BT                 | 1.01         | 0.45–2.29                |         |                                       |
| Circulatory                  | 0.93         | 0.74–1.16                |         |                                       |
| CVA                          | 1.04         | 0.91–1.18                |         |                                       |
| Drug overdose                | 0.93         | 0.75–1.15                |         |                                       |
| Intoxication                 | 3.11         | 1.00–9.70                |         |                                       |
| Meningitis                   | 0.56         | 0.21–1.53                |         |                                       |
| Respiratory                  | 1.24         | 1.03–1.49                |         |                                       |
| SAB                          | 2.32         | 0.96–5.61                |         |                                       |
| Sepsis                       | 0.77         | 0.19–3.10                |         |                                       |
| Donor history                |              |                          |         |                                       |
| Uncompromised                | 1.00         | –                        | 0.684   | 0.00                                  |
| Compromised                  | 1.03         | 0.89–1.20                |         |                                       |
| Hypertension                 |              |                          |         |                                       |
| No                           | 1.00         | –                        | 0.202   | 0.00                                  |
| Yes                          | 1.07         | 0.94–1.23                |         |                                       |
| Not available                | 1.49         | 0.89–2.48                |         |                                       |
| Cardiac arrest               |              |                          |         |                                       |
| No                           | 1.00         | –                        | 0.299   | 0.01                                  |
| Yes                          | 1.00         | 0.74–1.10                |         |                                       |
| LVEF (%)                     |              |                          |         |                                       |
| >55                          | 1.00         | –                        | 0.720   | 0.01                                  |
| 45–55                        | 0.98         | 0.88–1.09                |         |                                       |
| <45                          | 0.83         | 0.47–1.48                |         |                                       |
| Not available                | 0.77         | 0.43–1.36                |         |                                       |
| Coronary angiography         |              |                          |         |                                       |
| Normal                       | 1.00         | –                        | 0.332   | 0.02                                  |
| Irregularities               | 1.36         | 1.01–1.83                |         |                                       |
| 1-vessel stenosis            | 0.82         | 0.26–2.55                |         |                                       |
| >1-vessel stenosis           | 1.09         | 0.15–7.82                |         |                                       |
| Not available                | 0.98         | 0.86–1.11                |         |                                       |
| Serum sodium (mmol/l)        |              |                          |         |                                       |
| <130                         | 1.02         | 0.71–1.47                | 0.656   | 0.02                                  |
| 130–139                      | 0.96         | 0.84–1.10                |         |                                       |
| 140–149                      | 1.00         | –                        |         |                                       |
| 150–159                      | 1.00         | 0.90–1.12                |         |                                       |
| 160–164                      | 0.94         | 0.75–1.17                |         |                                       |
| 165–169                      | 1.23         | 0.91–1.67                |         |                                       |
| ≥170                         | 1.03         | 0.64–1.64                |         |                                       |
| Not available                | 1.96         | 0.81–4.76                |         |                                       |
| Norepinephrine (µg/kg/min)   |              |                          |         |                                       |
| <0.1                         | 1.00         | –                        | 0.235   | 0.03                                  |
| 0.1–0.4                      | 1.34         | 1.05–1.70                |         |                                       |
| 0.41–0.8                     | 0.97         | 0.49–1.96                |         |                                       |
| >0.8                         | 0.81         | 0.11–5.75                |         |                                       |
| Not available                | 1.02         | 0.90–1.15                |         |                                       |
Conclusions

Four conclusions can be drawn from this analysis. First, the aHDS accurately predicts donor organ discard for medical reasons in the UNOS registry and might be applied to standardize donor selection processes. Second, transplant physicians in the United States and in Europe base their decisions regarding donor organ discard or acceptance on similar donor characteristics. Third, the aHDS is similarly predictive in donors <60 years or ≥60 years of age. Only highly selected donors ≥60 years of age are accepted for HTX. Fourth, donor selection processes of transplant physicians in the United States seem to be highly accurate, thereby eliminating the potentially negative effects of most aHDS components and leaving only donor age with a significant and independent influence on 1-year survival after HTX.

Authorship

PA and AOZ: conceptualized the study. PA: prepared the datasets for statistical analysis and drafted the manuscript. AK: performed all statistical analyses. JMS: is the first author of the original publication of the HDS and provided scientific and statistical advice. AZA-Z and EO-J: critically reviewed and co-edited the manuscript. GL: provided resources as well as scientific advice.

Table 6. Continued.

| Variable | Hazard ratio | 95% Confidence interval | P-value | Proportion of explained variation (%) |
|----------|--------------|-------------------------|---------|---------------------------------------|
| Dopamine/dobutamine (µg/kg/min) | | | | |
| <5 | 1.00 | – | 0.257 | 0.02 |
| 5–7.5 | 1.16 | 0.98–1.37 | | |
| 7.51–10 | 1.05 | 0.80–1.38 | | |
| >10 | 1.05 | 0.63–1.75 | | |
| Not available | 1.13 | 0.99–1.30 | | |
| IMPACT score (log2-transformed) | 1.46 | 1.39–1.54 | <0.001 | 1.20 |
| Donor male sex | 0.96 | 0.87–1.07 | 0.478 | 0.00 |
| Recipient body mass index (kg/m²) | 1.02 | 1.01–1.03 | <0.001 | 0.07 |
| Recipient diabetes | 1.02 | 0.92–1.14 | 0.668 | 0.00 |
| Transplant year | 0.98 | 0.96–0.99 | 0.005 | 0.04 |
| Transplant urgency | | | | |
| Status 1A | 0.98 | 0.84–1.14 | 0.355 | 0.01 |
| Status 1B | 0.92 | 0.78–1.07 | | |
| Status 2 | 1.00 | – | | |
| Ischemic time (h) | 1.15 | 1.10–1.20 | <0.001 | 0.22 |

BT, brain tumor; CVA, cerebrovascular accident; HTX, heart transplantation; IMPACT, Index for Mortality Prediction after Cardiac Transplantation; LVEF, left-ventricular ejection fraction; SAB, subarachnoid bleeding.

Bold indicates statistical significance (P < 0.05).

Funding

This work was supported in part by Health Resources and Services Administration contract 234-2005-370011C.

Conflict of interest

Dr Zuckermann serves on the speakers’ bureau of Paragonix, Novartis, Mallincrodt, Sanofi-Genzyme, Franz Köhler Chemie and on the advisory board for Chiesi. Dr Aliabadi-Zuckermann received travel grants from Sanofi and institutional grant support from Fresenius. Dr Laufer is a consultant for Edwards Lifesciences. All other authors have nothing to disclose.

Acknowledgements

The data reported here have been supplied by the United Network for Organ Sharing as the contractor for the Organ Procurement and Transplantation Network. The content of this work is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Organ Procurement and Transplantation Network or the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the United States Government.
SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Figure S1. Derivation of the study cohort for donor organ discard.

Figure S2. Derivation of the study cohort for survival.

Figure S3. Survival out to 10 years after HTX.

REFERENCES

1. Mehra MR. Heart transplantation at 50. Lancet 2017; 390: e43.
2. Kittleson MM, Kobashigawa JA. Cardiac transplantation: current outcomes and contemporary controversies. JACC Heart Fail 2017; 5: 857.
3. Stevenson LW. Crisis awaiting heart transplantation: sinking the lifeboat. JAMA Intern Med 2015; 175: 1406.
4. Khush KK. Donor selection in the modern era. Ann Cardiotorac Surg 2018; 7: 126.
5. Kobashigawa J, Khush K, Colvin M, et al. Report from the American Society of Transplantation conference on donor heart selection in adult cardiac transplantation in the United States. Am J Transplant 2017; 17: 2559.
6. Smits JM, De Pauw M, de Vries E, et al. Donor scoring system for heart transplantation and the impact on patient survival. J Heart Lung Transplant 2012; 31: 387.
7. UNOS Deceased Donor Registration Worksheet.
8. Mehra MR, Jarche JA, Cherikh W, et al. The drug-intoxication epidemic and solid-organ transplantation. N Engl J Med 2018; 378: 1943.
9. Mehta HB, Mehta V, Girman CJ, Adhikari D, Johnson ML. Regression coefficient-based scoring system should be used to assign weights to the risk index. J Clin Epidemiol 2016; 79: 22.
10. Harrell F. Regression coefficients and scoring rules. J Clin Epidemiol 1996; 49: 819.
11. Heinze G, Dunkler D. Five myths about variable selection. Transpl Int 2017; 30: 6.
12. Weiss ES, Allen JG, Arnaoutakis GJ, et al. Creation of a quantitative recipient risk index for mortality prediction after cardiac transplantation (IMPACT). Ann Thorac Surg 2011; 92: 914; discussion 921-2.
13. Schepfer M, Henderson R. Predictive accuracy and explained variation in Cox regression. Biometrics 2000; 56: 249.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
15. Trivedi JR, Cheng A, Gallo M, et al. Predictors of donor heart utilization for transplantation in United States. Ann Thorac Surg 2017; 103: 1900.
16. Khush KK, Menza R, Nguyen J, Zaroff JG, Goldstein BA, Donor predictors of allograft use and recipient outcomes after heart transplantation. Circ Heart Fail 2013; 6: 300.
17. Khush KK, Potena L, Cherikh WS, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th annual report-2020; focus on deceased donor characteristics. J Heart Lung Transplant 2020; 39: 1003.
18. Weiss ES, Allen JG, Kilic A, et al. Development of a quantitative donor risk index to predict short-term mortality in orthotropic heart transplantation. J Heart Lung Transplant 2012; 31: 266.
19. Angleitner P, Kaider A, Gokler J, et al. High-dose catecholamine donor support and outcomes after heart transplantation. J Heart Lung Transplant 2018; 37: 596.
20. Sibona A, Khush KK, Oyoyo UE, et al. Long-term transplant outcomes of donor hearts with left ventricular dysfunction. J Thorac Cardiovasc Surg 2019; 157: 1865.
21. Chen CW, Sprys MH, Gaffey AC, et al. Low ejection fraction in donor hearts is not directly associated with increased recipient mortality. J Heart Lung Transplant 2017; 36: 611.
22. Benck U, Hoeger S, Brinkkoepter PT, et al. Effects of donor pre-treatment with dopamine on survival after heart transplantation: a cohort study of heart transplant recipients nested in a randomized controlled multicenter trial. J Am Coll Cardiol 2011; 58: 1768.
23. Graubhan O, Sniawski H, Dandel M, et al. Coronary atherosclerosis of the donor heart: impact on early graft failure. Eur J Cardiothorac Surg 2007; 32: 634.
24. Khush KK, Ball RL. Great variability in donor heart acceptance practices across the United States. Am J Transplant 2019; 20(6): 1582-1596. https://doi.org/10.1111/ajt.15760.
25. Smith JW, O’Brien KD, Dardas T, et al. Systematic donor selection review process improves cardiac transplant volumes and outcomes. J Thorac Cardiovasc Surg 2016; 151: 238.
26. Messer S, Cernic S, Page A, et al. A 5-year single-center early experience of heart transplantation from donation after circulatory-determined death donors. J Heart Lung Transplant 2020; 39: 1463.